Inhibrx, Inc.

INBX

US45720L1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
15.09 ^USD	-2.46%		+3.57%	-60.29%

06-04	Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	MT
05-31	Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	CI

Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index

May 30, 2024

Latest news about Inhibrx, Inc.

Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing	06-04	MT
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index	05-30	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Global BMI Index	05-30	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P TMI Index	05-30	CI
Inhibrx, Inc. Announces Termination of Loan Agreement	05-30	CI
Inhibrx, Inc. Announces Management Changes	05-30	CI
Sanofi Closes Purchase of US Biotech Company Inhibrx	05-30	MT
Sanofi: acquisition of Inhibrx finalized	05-30	CF
Aventis Inc. completed the acquisition of Inhibrx, Inc. from a group of shareholders.	05-29	CI
Inhibrx, Inc. completed the Spin-Off of 92% stake in Inhibrx Biosciences, Inc..	05-28	CI
Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index	05-28	CI
Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi	05-24	MT
Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Inhibrx Shares Fall After Q4 Net Loss Widens	02-28	MT
Earnings Flash (INBX) INHIBRX Reports Q4 Revenue $1.6M	02-28	MT
Inhibrx, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Inhibrx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Arecor Therapeutics hails Arestat as 2023 performance "strong"	02-01	AN
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results	01-24	DJ
Health Care Flat After J&J Earnings -- Health Care Roundup	01-23	DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi	01-23	AN
Sector Update: Health Care Stocks Decline Late Afternoon	01-23	MT
Sector Update: Health Care	01-23	MT
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion	01-23	MT
CAC40: slight decline in the absence of catalysts	01-23	CF

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Companyâs clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INHIBRX, INC.	-60.29%	1.79B
VERTEX PHARMACEUTICALS INCORPORATED	+16.45%	122B
REGENERON PHARMACEUTICALS, INC.	+21.96%	116B
ARGENX SE	+25.47%	27.03B
BIONTECH SE	-20.05%	20.36B
BEIGENE, LTD.	-16.28%	15.91B
GENMAB A/S	-15.94%	16.43B
WUXI APPTEC CO., LTD.	-44.35%	15.6B
SAREPTA THERAPEUTICS, INC.	+63.91%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+2.52%	13.59B